
Eplerenone (Inspra) 25mg and 50mg film-coated tablets

All Wales Medicines Strategy Group (AWMSG)

Record Status

This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

All Wales Medicines Strategy Group (AWMSG). Eplerenone (Inspra) 25mg and 50mg film-coated tablets. Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2712. 2012

Authors' conclusions

Eplerenone (Inspra®) is recommended as an option for use within NHS Wales in addition to standard optimal therapy, to reduce the risk of cardiovascular mortality and morbidity in adult patients with New York Heart Association (NYHA) class II (chronic) heart failure and left ventricular systolic dysfunction (LVEF \leq 30%).

Final publication URL

<http://www.wales.nhs.uk/sites3/Documents/371/eplerenone%20%28Inspra%29%20FAR.pdf>

Indexing Status

Subject indexing assigned by CRD

MeSH

Humans; Spironolactone; Mineralocorticoid Receptor Antagonists; Heart Failure; Ventricular Dysfunction, Left

Language Published

English

Country of organisation

Wales

English summary

An English language summary is available.

Address for correspondence

All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX Email: AWTTC@wales.nhs.uk

AccessionNumber

32013000329

Date abstract record published

10/05/2013